Developer docs
API playgroundTry for free, no card

Search company profiles

360biolabs

Full company profile

uuid000fd34

Namestring
360biolabs
Legal namestring
360biolabs Pty Ltd
Websiteurl
360biolabs.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

360biolabs is an Australian contract research organization (CRO) founded in 2015 in Melbourne that provides integrated bioanalytical laboratory services for early-phase clinical trials. Its service portfolio spans pharmacokinetics (via LC-MS/MS and immunoassays), pharmacodynamics (via flow cytometry, molecular assays, and soluble biomarkers), immunogenicity (screening, confirmatory, titer, and neutralizing antibody assays), biomarker analysis (500+ biomarkers across MSD, Simoa, Luminex, flow cytometry, qPCR/dPCR, and ELISpot platforms), vaccines and infectious diseases (BSL-2/BSL-3 virology including PRNT, MNT, FRNT, and pseudovirus assays), and central laboratory services (kit production, lab manuals, LIMS-controlled sample tracking, PBMC isolation, and 24/7 biobanking). The business operates from purpose-built facilities in Melbourne's Alfred Research Alliance precinct (approximately 3,000 sq m, including BSL-3 labs and 10+ LC-MS/MS instruments) and Brisbane's Translational Research Institute, with BSL-3 capability also co-located at the Burnet Institute. Revenue is generated through fee-for-service contracts on a per-project, per-study, or per-sample basis, with pricing negotiated by assay complexity, throughput, and regulatory requirements; ancillary managed-services revenue arises from central lab support. The customer base comprises pharmaceutical and biotechnology companies (primarily enterprise sponsors developing small molecules, biologics, vaccines, and cell/gene therapies), contract research organizations acting as indirect channels, and academic medical centers. International sponsors are a primary commercial focus, with go-to-market activity emphasizing the 'Australian Advantage': 4-6 week Phase 1 ethics approvals (no IND required), a 43.5% R&D tax incentive, up to 60% cost savings versus US trials, and Southern Hemisphere seasonal alignment for respiratory virus studies that can shorten timelines by up to 6 months.

The company was acquired in 2021 by BioAgilytix, a US-headquartered global bioanalytical services provider, with the combined network now operating six laboratories across Australia, the United States (Durham, Boston, San Diego), Germany (Hamburg), and partner laboratories in China. BioAgilytix leadership (CEO Davide Molho, previously COO of Charles River Laboratories and CEO of Viroclinics Biosciences) sits above 360biolabs' retained founding executive team: President Alistair Draffan (PhD, organic chemistry; ex-Director of Drug Discovery at Biota Pharmaceuticals), Executive Vice President of Scientific Operations Melinda Pryor (PhD, virology), and Executive Vice President of Commercial Angela Luttick. The integration provides 360biolabs' Phase 1 customers with a seamless pathway into BioAgilytix's US and European laboratories for Phase 2+ sample analysis without re-procurement, materially expanding the addressable market for both entities.

Operationally, 360biolabs is distinguished as the first Australian laboratory to develop and validate SARS-CoV-2 microneutralization assays in 2020 and has since supported 25+ SARS-CoV-2 clinical studies with over 60,000 samples received from international programs, 90+ vaccine clinical trials cumulatively (80% growth in non-COVID trials during 2020-2025), and 225+ infectious disease studies with 115,000+ samples analyzed during 2023-2025. Named customers include Novavax (Phase 3 COVID-19 variant trial with distributed PBMC processing across two Australian sites), Vaccitech (vaccine Phase 1 with reported 6-month timeline acceleration and 40% cost savings versus Europe), Diagenta (central lab start-up services), and Swinburne University (SARS-CoV-2 viricidal surface testing). NATA-accredited for ISO/IEC 17025, GLP, and GCLP, the company is positioned as the most comprehensive Australian bioanalytical CRO, though standalone revenue remains undisclosed, and the operating model is now tightly linked to parent BioAgilytix's global commercial pipeline.

Short descriptiontext

360biolabs is an Australian bioanalytical contract research organization (CRO) and subsidiary of BioAgilytix providing pharmacokinetic, pharmacodynamic, immunogenicity, biomarker, vaccine/infectious disease, and central laboratory services for early-phase clinical trials of pharmaceutical and biotechnology sponsors globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersMelbourne, Australia
HQ citystring
Melbourne
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bioanalytical laboratory services, clinical trial sample testing, pharmacokinetic assay services, immunogenicity testing services, contract research organization
Industry3 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Medical Laboratories621511
  • Scientific Research and Development Services5417
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
Product category
Bioanalytical Contract Research Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services
TypeProfessional Services
Description

360biolabs operates as a contract research organization providing bioanalytical laboratory services for clinical trials. Revenue is generated through fee-for-service contracts for assay development, validation, and sample testing across pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers, and infectious disease services. Services are billed per project, study, or sample basis with pricing based on assay complexity, throughput, and regulatory requirements.

360biolabs.com
2Central Laboratory Services
TypeManaged Services
Description

Additional revenue streams include central laboratory services such as kit production, laboratory manual development, sample management, biobanking, and logistics coordination. These operational support services complement core bioanalytical testing.

360biolabs.com
Marketing channels9 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

360biolabs is Australia's most comprehensive bioanalytical contract research organization (CRO) providing pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity, biomarker, vaccine and infectious disease, and central laboratory services for early-phase clinical trials. It delivers assay development, validation, and sample testing across LC-MS/MS, flow cytometry, PCR, immunoassay, and virology platforms for pharmaceutical and biotechnology sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 7 values shown
  • 60% cost savings vs US trials
+6 more records
Product overview1 text field

360biolabs is Australia's most comprehensive bioanalytical laboratory offering a unified suite of pharmacokinetic and pharmacodynamic assay services for early-phase clinical studies. The core portfolio consists of Pharmacokinetics, Pharmacodynamics, Immunogenicity, Biomarkers, Vaccines & Infectious Diseases, and Central Lab Services. Pharmacokinetics encompasses LC-MS/MS and immunoassay/ligand-binding assay capabilities. Pharmacodynamics includes flow cytometry and molecular assays. Immunogenicity covers anti-drug antibody (ADA) and neutralizing antibody (NAb) testing. The service offering integrates Central Lab Services (Kit Production, Lab Manuals, PBMC Isolation, biobanking), Biomarkers (using MSD, Simoa, Luminex platforms), Vaccines & Infectious Diseases (virology assays, neutralization tests), and Flow Cytometry (high-parameter single-cell analysis). Molecular Assays provide qPCR, dPCR, and gene expression analysis. LC-MS/MS supports both small and large molecule bioanalysis. All services operate under GLP, GCP, and ISO/IEC 17025 quality standards with global support from BioAgilytix laboratories for Phase 2+ studies.

Product and service11 records
1Pharmacokinetics (PK)
CategoryBioanalytical Services
Description

Comprehensive pharmacokinetic assay development, validation, and sample testing services for various drug modalities and sample types, utilizing LC-MS/MS and immunoassay platforms to support clinical pharmacology studies for pharmaceutical and biotechnology sponsors.

2Pharmacodynamics (PD)
CategoryBioanalytical Services
Description

Pharmacodynamic biomarker assessments measuring how drugs affect biological systems, including soluble biomarkers, molecular events, and cellular phenotyping via flow cytometry. Used by pharma and biotech sponsors to demonstrate proof of mechanism and dose response in early-phase clinical trials.

3Immunogenicity
CategoryBioanalytical Services
Description

Assessment of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for biotherapeutics using multi-tiered screening, confirmatory, titer, and characterization assays compliant with FDA/EMA regulatory standards. Targeted at sponsors developing biologics and biotherapeutics.

4Biomarkers
CategoryBioanalytical Services
Description

Biomarker analysis for therapeutic efficacy, safety, and mechanism-of-action assessment using LC-MS/MS, ligand-binding assays (MSD, Simoa, Luminex), and flow cytometry across multiple matrices. Supports therapeutic development programs across a wide range of disease states.

5Vaccines and Infectious Diseases
CategoryBioanalytical Services
Description

Comprehensive virology and infectious disease services including culture-based assays (TCID50, Plaque Assay), neutralization tests (PRNT, MNT, FRNT), ELISpot, HAI assays, and molecular diagnostics for vaccine development and pathogen research. Used by vaccine developers and infectious disease researchers.

6Central Lab Services
CategoryCentral Laboratory Services
Description

Integrated central laboratory services encompassing protocol-specific kit production, laboratory manuals, LIMS-controlled sample tracking, PBMC isolation, and 24/7 monitored biobanking for multi-site clinical trials. Provides end-to-end operational support for clinical study sponsors.

7LC-MS/MS Bioanalysis
CategoryBioanalytical Services
Description

Liquid chromatography-mass spectrometry services for separation, identification, and quantification of small and large molecules, metabolites, peptides, proteins, ADCs, oligonucleotides, siRNA, and lipid nanoparticles for clinical and preclinical drug development.

8Flow Cytometry
CategoryBioanalytical Services
Description

High-parameter single-cell analysis using Fortessa and Canto II flow cytometers for receptor occupancy, biomarker expression, immunophenotyping, cell enumeration, cytokine analysis, and minimal residual disease detection in clinical trial samples.

9Molecular Assays
CategoryBioanalytical Services
Description

Real-time PCR, quantitative PCR (qPCR), and digital PCR (dPCR) services for pharmacokinetic studies of RNA-based therapeutics, cell and gene therapy solutions, gene expression analysis, viral shedding, biodistribution studies, and pathogen detection.

10Ligand-binding Assays / Immunoassays
CategoryBioanalytical Services
Description

Custom immunoassay development and validation across various methodologies including MSD-ECL, Simoa, and Luminex platforms to support clinical therapeutic programs for large molecules, advanced therapies, and vaccines.

11PBMC Isolation
Scale indicator14 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

360biolabs was acquired by BioAgilytix in 2021, creating a global bioanalytical network with laboratories in Australia, USA, and Europe. This partnership enables seamless transition of assays from Phase 1 in Australia to Phase 2+ in international locations. The acquisition expanded 360biolabs' service offering and provided access to global client base and additional technical capabilities.

Recent move10 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based clinical pharmacology CRO specializing in early-phase clinical pharmacology and bioanalytical services for pharma and biotech. Directly comparable to 360biolabs in early-phase PK/PD/biomarker positioning, with similar global sponsor customer base.

TypeDirect peer
Description

Parent network of 360biolabs and the company's primary peer in head-to-head bioanalytical services. Operates large-molecule bioanalysis, immunogenicity, biomarkers, and cell/gene therapy assays across US and EU hubs, providing the exact same service catalog 360biolabs offers in Australia.

TypeDirect peer
Description

Global bioanalytical CRO and part of the broader Eurofins lab network. Offers small/large molecule bioanalysis, immunogenicity, and biomarker services for pharma sponsors — a direct functional competitor for bioanalytical contracts that 360biolabs targets.

TypeDirect peer
Description

US-headquartered CRO with bioanalytical, biomarker, and CMC services. Comparable in offering bioanalytical support to pharma/biotech sponsors and competes for similar Phase 1 immunogenicity and PK assay mandates.

TypeDirect peer
Description

Preclinical and bioanalytical CRO with particular depth in LC-MS/MS small/large molecule bioanalysis and PK/PD services. Directly comparable scale and therapeutic-area focus to 360biolabs.

TypeDirect peer
Description

Mid-sized global CRO with strong bioanalytical and early-phase clinical pharmacology offerings, comparable in serving biotech and pharma sponsors across Phase 1-2 mandates.

TypeBroad incumbent
Description

Large global CRO/CDMO with end-to-end drug development services. BioAgilytix CEO Davide Molho previously served as President and COO at Charles River, highlighting the close competitive and talent overlap with 360biolabs' parent in early-phase bioanalysis.

TypeBroad incumbent
Description

World's largest CRO with full Phase 1-4 capabilities including central labs and bioanalytical services. Represents the largest incumbent competitor 360biolabs could face on multi-region Phase 2+ expansions.

TypeBroad incumbent
Description

Major global CRO with central laboratory services and early-phase clinical pharmacology capabilities. Competes for full-service clinical trial work that 360biolabs hands off from Phase 1 to Phase 2+.

TypeBroad incumbent
Description

China-based global CRO/CDMO with bioanalytical services and partner-lab footprint referenced in 360biolabs' Beijing operations. Represents a broader global incumbent in CRO/CDMO space that competes for Asia-Pacific sponsors.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature9 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

360biolabs

Bioanalytical Contract Research Services360biolabs.com

360biolabs is an Australian bioanalytical contract research organization (CRO) and subsidiary of BioAgilytix providing pharmacokinetic, pharmacodynamic, immunogenicity, biomarker, vaccine/infectious disease, and central laboratory services for early-phase clinical trials of pharmaceutical and biotechnology sponsors globally.

What 360biolabs does

360biolabs is an Australian contract research organization (CRO) founded in 2015 in Melbourne that provides integrated bioanalytical laboratory services for early-phase clinical trials. Its service portfolio spans pharmacokinetics (via LC-MS/MS and immunoassays), pharmacodynamics (via flow cytometry, molecular assays, and soluble biomarkers), immunogenicity (screening, confirmatory, titer, and neutralizing antibody assays), biomarker analysis (500+ biomarkers across MSD, Simoa, Luminex, flow cytometry, qPCR/dPCR, and ELISpot platforms), vaccines and infectious diseases (BSL-2/BSL-3 virology including PRNT, MNT, FRNT, and pseudovirus assays), and central laboratory services (kit production, lab manuals, LIMS-controlled sample tracking, PBMC isolation, and 24/7 biobanking). The business operates from purpose-built facilities in Melbourne's Alfred Research Alliance precinct (approximately 3,000 sq m, including BSL-3 labs and 10+ LC-MS/MS instruments) and Brisbane's Translational Research Institute, with BSL-3 capability also co-located at the Burnet Institute. Revenue is generated through fee-for-service contracts on a per-project, per-study, or per-sample basis, with pricing negotiated by assay complexity, throughput, and regulatory requirements; ancillary managed-services revenue arises from central lab support. The customer base comprises pharmaceutical and biotechnology companies (primarily enterprise sponsors developing small molecules, biologics, vaccines, and cell/gene therapies), contract research organizations acting as indirect channels, and academic medical centers. International sponsors are a primary commercial focus, with go-to-market activity emphasizing the 'Australian Advantage': 4-6 week Phase 1 ethics approvals (no IND required), a 43.5% R&D tax incentive, up to 60% cost savings versus US trials, and Southern Hemisphere seasonal alignment for respiratory virus studies that can shorten timelines by up to 6 months.

The company was acquired in 2021 by BioAgilytix, a US-headquartered global bioanalytical services provider, with the combined network now operating six laboratories across Australia, the United States (Durham, Boston, San Diego), Germany (Hamburg), and partner laboratories in China. BioAgilytix leadership (CEO Davide Molho, previously COO of Charles River Laboratories and CEO of Viroclinics Biosciences) sits above 360biolabs' retained founding executive team: President Alistair Draffan (PhD, organic chemistry; ex-Director of Drug Discovery at Biota Pharmaceuticals), Executive Vice President of Scientific Operations Melinda Pryor (PhD, virology), and Executive Vice President of Commercial Angela Luttick. The integration provides 360biolabs' Phase 1 customers with a seamless pathway into BioAgilytix's US and European laboratories for Phase 2+ sample analysis without re-procurement, materially expanding the addressable market for both entities.

Operationally, 360biolabs is distinguished as the first Australian laboratory to develop and validate SARS-CoV-2 microneutralization assays in 2020 and has since supported 25+ SARS-CoV-2 clinical studies with over 60,000 samples received from international programs, 90+ vaccine clinical trials cumulatively (80% growth in non-COVID trials during 2020-2025), and 225+ infectious disease studies with 115,000+ samples analyzed during 2023-2025. Named customers include Novavax (Phase 3 COVID-19 variant trial with distributed PBMC processing across two Australian sites), Vaccitech (vaccine Phase 1 with reported 6-month timeline acceleration and 40% cost savings versus Europe), Diagenta (central lab start-up services), and Swinburne University (SARS-CoV-2 viricidal surface testing). NATA-accredited for ISO/IEC 17025, GLP, and GCLP, the company is positioned as the most comprehensive Australian bioanalytical CRO, though standalone revenue remains undisclosed, and the operating model is now tightly linked to parent BioAgilytix's global commercial pipeline.

360biolabs firmographics

Firmographics
Name
360biolabs
Legal name
360biolabs Pty Ltd
Website
https://360biolabs.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
101–250 employees
Short description
360biolabs is an Australian bioanalytical contract research organization (CRO) and subsidiary of BioAgilytix providing pharmacokinetic, pharmacodynamic, immunogenicity, biomarker, vaccine/infectious disease, and central laboratory services for early-phase clinical trials of pharmaceutical and biotechnology sponsors globally.
Ownership category
akta.pro rank

360biolabs industry classification

Industry
Product category
Bioanalytical Contract Research Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAGAAAA
Clinical CROs (Phase I–IV)
SECONDARYHLAGAAAE
Central Laboratory & Clinical Trial Testing CROs

Keywords

  • Bioanalytical laboratory services
  • Clinical trial sample testing
  • Pharmacokinetic assay services
  • Immunogenicity testing services
  • Contract research organization

Where 360biolabs is headquartered

Location

Headquarters

HQ city
Melbourne
HQ country
Australia
HQ region
Oceania

Offices8 records

Markets served

360biolabs business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Research Services: 360biolabs operates as a contract research organization providing bioanalytical laboratory services for clinical trials. Revenue is generated through fee-for-service contracts for assay development, validation, and sample testing across pharmacokinetics, pharmacodynamics, immunogenicity, biomarkers, and infectious disease services. Services are billed per project, study, or sample basis with pricing based on assay complexity, throughput, and regulatory requirements.
  2. Central Laboratory Services: Additional revenue streams include central laboratory services such as kit production, laboratory manual development, sample management, biobanking, and logistics coordination. These operational support services complement core bioanalytical testing.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels9 records

360biolabs product offering

Product offering

Core offering

360biolabs is Australia's most comprehensive bioanalytical contract research organization (CRO) providing pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity, biomarker, vaccine and infectious disease, and central laboratory services for early-phase clinical trials. It delivers assay development, validation, and sample testing across LC-MS/MS, flow cytometry, PCR, immunoassay, and virology platforms for pharmaceutical and biotechnology sponsors.

Product overview

360biolabs is Australia's most comprehensive bioanalytical laboratory offering a unified suite of pharmacokinetic and pharmacodynamic assay services for early-phase clinical studies. The core portfolio consists of Pharmacokinetics, Pharmacodynamics, Immunogenicity, Biomarkers, Vaccines & Infectious Diseases, and Central Lab Services. Pharmacokinetics encompasses LC-MS/MS and immunoassay/ligand-binding assay capabilities. Pharmacodynamics includes flow cytometry and molecular assays. Immunogenicity covers anti-drug antibody (ADA) and neutralizing antibody (NAb) testing. The service offering integrates Central Lab Services (Kit Production, Lab Manuals, PBMC Isolation, biobanking), Biomarkers (using MSD, Simoa, Luminex platforms), Vaccines & Infectious Diseases (virology assays, neutralization tests), and Flow Cytometry (high-parameter single-cell analysis). Molecular Assays provide qPCR, dPCR, and gene expression analysis. LC-MS/MS supports both small and large molecule bioanalysis. All services operate under GLP, GCP, and ISO/IEC 17025 quality standards with global support from BioAgilytix laboratories for Phase 2+ studies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Pharmacokinetics (PK) Comprehensive pharmacokinetic assay development, validation, and sample testing services for various drug modalities and sample types, utilizing LC-MS/MS and immunoassay platforms to support clinical pharmacology studies for pharmaceutical and biotechnology sponsors.
  • Pharmacodynamics (PD) Pharmacodynamic biomarker assessments measuring how drugs affect biological systems, including soluble biomarkers, molecular events, and cellular phenotyping via flow cytometry. Used by pharma and biotech sponsors to demonstrate proof of mechanism and dose response in early-phase clinical trials.
  • Immunogenicity Assessment of anti-drug antibodies (ADAs) and neutralizing antibodies (NAbs) for biotherapeutics using multi-tiered screening, confirmatory, titer, and characterization assays compliant with FDA/EMA regulatory standards. Targeted at sponsors developing biologics and biotherapeutics.
  • Biomarkers Biomarker analysis for therapeutic efficacy, safety, and mechanism-of-action assessment using LC-MS/MS, ligand-binding assays (MSD, Simoa, Luminex), and flow cytometry across multiple matrices. Supports therapeutic development programs across a wide range of disease states.
  • Vaccines and Infectious Diseases Comprehensive virology and infectious disease services including culture-based assays (TCID50, Plaque Assay), neutralization tests (PRNT, MNT, FRNT), ELISpot, HAI assays, and molecular diagnostics for vaccine development and pathogen research. Used by vaccine developers and infectious disease researchers.
  • Central Lab Services Integrated central laboratory services encompassing protocol-specific kit production, laboratory manuals, LIMS-controlled sample tracking, PBMC isolation, and 24/7 monitored biobanking for multi-site clinical trials. Provides end-to-end operational support for clinical study sponsors.
  • LC-MS/MS Bioanalysis Liquid chromatography-mass spectrometry services for separation, identification, and quantification of small and large molecules, metabolites, peptides, proteins, ADCs, oligonucleotides, siRNA, and lipid nanoparticles for clinical and preclinical drug development.
  • Flow Cytometry High-parameter single-cell analysis using Fortessa and Canto II flow cytometers for receptor occupancy, biomarker expression, immunophenotyping, cell enumeration, cytokine analysis, and minimal residual disease detection in clinical trial samples.
  • Molecular Assays Real-time PCR, quantitative PCR (qPCR), and digital PCR (dPCR) services for pharmacokinetic studies of RNA-based therapeutics, cell and gene therapy solutions, gene expression analysis, viral shedding, biodistribution studies, and pathogen detection.
  • Ligand-binding Assays / Immunoassays Custom immunoassay development and validation across various methodologies including MSD-ECL, Simoa, and Luminex platforms to support clinical therapeutic programs for large molecules, advanced therapies, and vaccines.
  • PBMC Isolation

Quantifiable outcome

  • 60% cost savings vs US trials
  • +6 more outcomes

Companies that use 360biolabs

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

360biolabs technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature9 records

360biolabs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioAgilytixcoreStrategic or Co-development Partner · 1 January 2021360biolabs was acquired by BioAgilytix in 2021, creating a global bioanalytical network with laboratories in Australia, USA, and Europe. This partnership enables seamless transition of assays from Phase 1 in Australia to Phase 2+ in international locations. The acquisition expanded 360biolabs' service offering and provided access to global client base and additional technical capabilities.

Scale indicators14 records

Recent moves10 records

Expansion highlights7 records

360biolabs competitors and assessment

Company assessment

Direct peers

  • Celerion: US-based clinical pharmacology CRO specializing in early-phase clinical pharmacology and bioanalytical services for pharma and biotech. Directly comparable to 360biolabs in early-phase PK/PD/biomarker positioning, with similar global sponsor customer base.
  • BioAgilytix: Parent network of 360biolabs and the company's primary peer in head-to-head bioanalytical services. Operates large-molecule bioanalysis, immunogenicity, biomarkers, and cell/gene therapy assays across US and EU hubs, providing the exact same service catalog 360biolabs offers in Australia.
  • Eurofins Bioanalytical Services: Global bioanalytical CRO and part of the broader Eurofins lab network. Offers small/large molecule bioanalysis, immunogenicity, and biomarker services for pharma sponsors — a direct functional competitor for bioanalytical contracts that 360biolabs targets.
  • Frontage Laboratories: US-headquartered CRO with bioanalytical, biomarker, and CMC services. Comparable in offering bioanalytical support to pharma/biotech sponsors and competes for similar Phase 1 immunogenicity and PK assay mandates.
  • Inotiv (Absorption Systems): Preclinical and bioanalytical CRO with particular depth in LC-MS/MS small/large molecule bioanalysis and PK/PD services. Directly comparable scale and therapeutic-area focus to 360biolabs.
  • Worldwide Clinical Trials: Mid-sized global CRO with strong bioanalytical and early-phase clinical pharmacology offerings, comparable in serving biotech and pharma sponsors across Phase 1-2 mandates.

Broad incumbents

  • Charles River Laboratories: Large global CRO/CDMO with end-to-end drug development services. BioAgilytix CEO Davide Molho previously served as President and COO at Charles River, highlighting the close competitive and talent overlap with 360biolabs' parent in early-phase bioanalysis.
  • IQVIA: World's largest CRO with full Phase 1-4 capabilities including central labs and bioanalytical services. Represents the largest incumbent competitor 360biolabs could face on multi-region Phase 2+ expansions.
  • Labcorp Drug Development (Covance): Major global CRO with central laboratory services and early-phase clinical pharmacology capabilities. Competes for full-service clinical trial work that 360biolabs hands off from Phase 1 to Phase 2+.
  • WuXi AppTec: China-based global CRO/CDMO with bioanalytical services and partner-lab footprint referenced in 360biolabs' Beijing operations. Represents a broader global incumbent in CRO/CDMO space that competes for Asia-Pacific sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

360biolabs social profiles

Digital presence

360biolabs compliance and trust

Trust signal

Compliance3 records

360biolabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

360biolabs leadership team

Management profile

Number of profiles

Profiles4 records

360biolabs funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

360biolabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about 360biolabs

What does 360biolabs do?

360biolabs is Australia's most comprehensive bioanalytical contract research organization (CRO) providing pharmacokinetic (PK), pharmacodynamic (PD), immunogenicity, biomarker, vaccine and infectious disease, and central laboratory services for early-phase clinical trials. It delivers assay development, validation, and sample testing across LC-MS/MS, flow cytometry, PCR, immunoassay, and virology platforms for pharmaceutical and biotechnology sponsors.

Is 360biolabs a public or private company?

360biolabs is a private company. It is classified as corporate owned and is currently operating.

When was 360biolabs founded?

360biolabs was founded in 2015. It employs 101 to 250 people.

Where is 360biolabs based?

360biolabs is headquartered in Melbourne, Australia, in the Oceania region.

How does 360biolabs make money?

Two revenue lines are on record. Contract Research Services are the primary driver. The others are central Laboratory Services.

Who are 360biolabs's main competitors?

Direct peers on record are Celerion, BioAgilytix, Eurofins Bioanalytical Services, Frontage Laboratories, Inotiv (Absorption Systems) and Worldwide Clinical Trials. Broad incumbents are Charles River Laboratories, IQVIA, Labcorp Drug Development (Covance) and WuXi AppTec.

Does 360biolabs have an API?

No public API is recorded for 360biolabs.

What industry is 360biolabs in?

360biolabs's product category is Bioanalytical Contract Research Services. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAGAAAA, Clinical CROs (Phase I–IV). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EIN PresswireBioAgilytix Expands Global Bioanalytical Capabilities Through New 360biolabs Sydney LaboratoryBioAgilytix opened a new purpose-designed BSL-2 laboratory for its 360biolabs subsidiary in Sydney, Australia, to support early-phase clinical development. The facility, located in Macquarie Park, is NATA-accredited to ISO/IEC 17025 and strengthens BioAgilytix's global bioanalytical capabilities.EIN PresswireBioAgilytix Expands Global Bioanalytical Capabilities Through New 360biolabs Sydney LaboratoryBioAgilytix opened a new purpose-designed laboratory for its 360biolabs subsidiary in Sydney, Australia, within the Macquarie Park Innovation District. The BSL-2 facility supports PBMC isolation, flow cytometry, and cryostorage, and is accredited to ISO/IEC 17025. The expansion strengthens BioAgilytix's global bioanalytical capabilities for early-phase clinical development.PR NewswireBioAgilytix Closes Acquisition of Australia-based 360biolabs®BioAgilytix Labs has officially closed its acquisition of Australia-based 360biolabs following approval from the Australian Foreign Investment Review Board. This transaction expands BioAgilytix's global bioanalytical capabilities by integrating 360biolabs' virology, immunology, and small molecule expertise into its existing network of laboratories.PR NewswireBioAgilytix to Purchase Australia-based 360biolabs®BioAgilytix signed a definitive agreement to purchase Australia-based 360biolabs, expanding its global footprint into Australia for first-in-human and early-phase trials. The acquisition, subject to FIRB approval, is expected to close in the third quarter of 2021.BioSpaceBioAgilytix to Purchase Australia-based 360biolabs®BioAgilytix Labs signed a definitive agreement to acquire 360biolabs, an Australian contract research organization, to expand its global footprint into the Asia-Pacific region. The transaction aims to enhance BioAgilytix's capabilities in early-phase clinical trials and bioanalytical services by leveraging 360biolabs' specialized laboratories and expertise in Melbourne. Subject to approval from the Australian Foreign Investment Review Board, the deal is expected to close in the third quarter of 2021.The Korea HeraldBioAgilytix to Purchase Australia-based 360biolabs®BioAgilytix Labs has signed a definitive agreement to acquire Australia-based 360biolabs, expanding its global bioanalytical services footprint into the Asia-Pacific region. The transaction, which adds specialized virology and immunology capabilities in Melbourne, is subject to Australian Foreign Investment Review Board approval and is expected to close in the third quarter of 2021.PR Newswire3D Printed ACTIVAT3D Copper Proven to Kill SARS-Cov-2 Virus on Contact SurfacesAustralian company SPEE3D has developed and tested ACTIVAT3D copper, a 3D printing process that coats metal surfaces with anti-microbial copper, demonstrating in laboratory testing that 96% of SARS-CoV-2 was killed in two hours and 99.2% in five hours, compared to stainless steel which showed no reduction. The technology was tested by 360Biolabs and has been deployed at multiple universities in Australia, the USA, and Japan for installation on high-touch surfaces such as door handles and touch plates. National Energy Resources Australia (NERA) funded and supported the testing as part of a global research collaboration aimed at reducing fomite transmission in public spaces.